Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP705 in Facial Cutaneous Squamous Cell Carcinoma in Situ
NCT05421013Phase 2Terminated
- Sponsor
- Sirnaomics
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of sirna-tgf-b1 + sirna-cox-2 in cutaneous squamous cell carcinoma in situ (SCCIS), sponsored by Sirnaomics. Started Aug 2022; status: terminated.
02
Drugs
sirna-tgf-b1 + sirna-cox-2
03
Conditions
cutaneous squamous cell carcinoma in situ (SCCIS)
Beyond the preview
Go deeper on NCT05421013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421013.